



## **WORSHIPFUL SOCIETY OF APOTHECARIES OF LONDON FACULTY OF CONFLICT AND CATASTROPHE MEDICINE**

### **Covid-19/SARS-CoV-2: References, Resources & Guidance**

[Updated 12/05/2020 – items added since the last update are placed in the “New Items” section at the beginning and then moved to the relevant section in the next issue]

[Disclaimers: This is not a complete or comprehensive listing and it is not intended to compete with the huge resources of medical libraries nor the specific guidance of professional bodies. It is intended to provide a “Go To” resource containing publications and links from a wide range of sources, that may be of practical use to health care workers dealing with the COVID-19 epidemic.

We will update this regularly and this will work best if you, the users, feed back to us. So if you know of any useful references or resources that are not included, or if you are aware that any of the references or resources listed are out of date or have been superseded, please let us know so that we can put them in, change them or cut them out!

(Inclusion of a title in this listing does not imply approval, endorsement or certification of the work or results therein by the Faculty of Conflict and Catastrophe Medicine or the Worshipful Society of Apothecaries of London. The items are included for information only and should be evaluated by the readers before use. When reading items published in printed or on-line journals, please bear in mind that the peer review process may have been curtailed or that an item may be a preprint that has not been certified by peer review. Such reports of new medical research may not yet have been evaluated and so should not be used to guide clinical practice).].

Contacts:

Faculty of Conflict & Catastrophe Medicine: [facultycc@apothecaries.org](mailto:facultycc@apothecaries.org)

Dr Tim Healing: [drtimhealing@hotmail.com](mailto:drtimhealing@hotmail.com)

## NEW ADDITIONS

Arulkumaran N. **Use of non-invasive ventilation for patients with COVID-19: a cause for concern?** The Lancet Respiratory Medicine. 20 April 2020.  
[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30181-8/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30181-8/fulltext)

Beigel JH et al. **Remdesivir for the Treatment of Covid-19 — Preliminary Report.** New England Journal of Medicine 22 May 2020  
<https://www.nejm.org/doi/10.1056/NEJMoa2007764>

Faust JS, del Rio C. **Assessment of Deaths From COVID-19 and From Seasonal Influenza.** *JAMA Intern Med.* Published online May 14, 2020.  
doi:10.1001/jamainternmed.2020.2306  
<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2766121>

Mehra MR et al. **Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.** The Lancet 22 May 2020. DOI:[https://doi.org/10.1016/S0140-6736\(20\)31180-6](https://doi.org/10.1016/S0140-6736(20)31180-6)

Netherlands Government. **COVID-19 on Mink Farms.**  
<https://www.government.nl/latest/news/2020/05/19/new-results-from-research-into-covid-19-on-mink-farms>

Walton M, Murray E, Christian MD. **Mental health care for medical staff and affiliated healthcare workers during the COVID-19 pandemic** [published online ahead of print, 2020 Apr 28]. *Eur Heart J Acute Cardiovasc Care.* 2020;2048872620922795.  
<https://pubmed.ncbi.nlm.nih.gov/32342698/>

WHO. **Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance,** 24 March 2020.  
<https://apps.who.int/iris/handle/10665/331538>

## RESOURCES & GUIDANCE

CIDRAP (Centre for Infectious Disease Research and Policy). **COVID-19 Maps & visuals.** <https://www.cidrap.umn.edu/covid-19/maps-visuals>

John Hopkins University. **Coronavirus resource center.**  
<https://coronavirus.jhu.edu/>

LSHTM. **COVID-19** <https://www.lshtm.ac.uk/research/research-action/covid-19>  
RCGP learning. **Covid-19 resource hub.**  
<https://elearning.rcgp.org.uk/course/view.php?id=373>

Medscape UK. **COVID-19.** [https://www.medscape.com/resource/uk-coronavirus?src=ban\\_ret\\_ukcovid\\_728x90\\_desk\\_03172020\\_int](https://www.medscape.com/resource/uk-coronavirus?src=ban_ret_ukcovid_728x90_desk_03172020_int)

ProMED. (International Society for Infectious Diseases - ISID). *(The Program for Monitoring Emerging Diseases (ProMED) is a program of ISID. It is an Internet service to identify unusual health events related to emerging and re-emerging infectious diseases and toxins affecting humans, animals and plants. It is the largest publicly-available system conducting global reporting of infectious diseases outbreaks)* <https://promedmail.org/about-promed/>

Royal College of Physicians and Surgeons of Glasgow. **Covid-19 Resource pages.** <https://rcpsg.ac.uk/covid-19>

Royal College of Surgeons. **Covid-19 Information hub.**  
<https://www.rcseng.ac.uk/coronavirus/>  
<https://www.rcseng.ac.uk/coronavirus/coronavirus-resources/>  
<https://www.rcseng.ac.uk/dental-faculties/fds/coronavirus/>

Royal College of Surgeons. **Covid-19. Guidance for surgeons working during the pandemic.** <https://www.rcseng.ac.uk/coronavirus/joint-guidance-for-surgeons-v2/>

University of Oxford. **Coronavirus Research.**  
<https://www.research.ox.ac.uk/Area/coronavirus-research>

UK Research and Innovation (UKRI). **Coronavirus: the science explained.**  
<https://coronavirusexplained.ukri.org/en/>

WHO. **Country and technical guidance – Coronavirus disease (COVID-19).**  
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance>

WHO. **Global Alert and Response Network (GOARN) Knowledge Hub.**  
<https://extranet.who.int/goarn/COVID19Hub>

WHO. **Rolling updates on coronavirus disease (COVID-19).** (Updated 15 April 2020). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>

WHO. **COVID-19 dashboard.**  
<https://who.sprinklr.com/>

## Journals

**BMJ's Coronavirus (Covid-19) Hub.** This hub supports health professionals and researchers with practical guidance, online CPD courses, as well as the latest news, comment, and research from BMJ. The content is free and updated daily.  
<https://www.bmj.com/coronavirus>

Journal of the American Medical Association. **JAMA Network. Coronavirus (COVID19).** (COVID-19 diagnosis and treatment).

<https://jamanetwork.com/collections/46099/coronavirus-covid19>

**Lancet Coronavirus Resource Centre.** This resource brings together new 2019 novel coronavirus disease (COVID-19) content from across *The Lancet* journals as it is published. (All of the Lancet COVID-19 content is free to access).

<https://www.thelancet.com/coronavirus>

**Nature Medicine.** (Covid Research in Brief. (A weekly roundup of how science is responding to COVID-19). <https://www.nature.com/nm/>

**New England Journal of Medicine. Coronavirus (Covid-19).** A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary. All *Journal* content related to the Covid-19 pandemic is freely available.

<https://www.nejm.org/coronavirus>

## CLINICAL MATTERS

### Clinical characteristics/Symptoms

Chen T. et al. **Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.**

*BMJ* 2020; 368 doi: <https://doi.org/10.1136/bmj.m1091> (Published 26 March 2020)

Galvan-Casas C. et al. **Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.**

*Br J Dermatol.* 2020 Apr 29. doi: 10.1111/bjd.19163. [Epub ahead of print].

<https://www.ncbi.nlm.nih.gov/pubmed/32348545>

Guan W et al. **Clinical Characteristics of Coronavirus Disease 2019 in China.** *New England Journal of Medicine.* Feb28,2020.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2002032>

Huang C. *et al.* **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.** *Lancet* 395 Feb 15, 2020.

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)

Richardson S et al. **Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area**

*JAMA.* Published online April 22, 2020. doi:10.1001/jama.2020.6775

<https://jamanetwork.com/journals/jama/fullarticle/2765184>

Roberts M & Colleagues. **Covid-19: a complex multisystem clinical syndrome.** The bmj opinion. 1 May.2020. <https://blogs.bmj.com/bmj/2020/05/01/covid-19-a-complex-multisystem-clinical-syndrome/>

Shi, Y., Yu, X., Zhao, H. *et al.* **Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan.** *Crit Care* **24**, 108 (2020). <https://doi.org/10.1186/s13054-020-2833-7>

Vincent J-L, Taccone FS. **Understanding pathways to death in patients with COVID-19.** The Lancet Respiratory Medicine 6 April 2020.  
DOI:[https://doi.org/10.1016/S2213-2600\(20\)30165-X](https://doi.org/10.1016/S2213-2600(20)30165-X)

### Management of cases

CDC Atlanta. **Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19).** Updated 3 April 2020.  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>

NHS England. **Clinical Management of persons admitted to hospital with suspected COVID-19 infection.** 19 March 2020.  
<https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020.pdf>

NICE. **COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community.** <https://www.nice.org.uk/guidance/ng165>

Phua J et al. **Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.** The Lancet 6 April 2020.  
[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30161-2/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30161-2/fulltext)

Public Health England. **COVID-19: investigation and initial clinical management of possible cases.** (Updated 6 April 2020).  
<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection>

Royal College of Nursing. **Clinical guidance for managing COVID-19.**  
<https://www.rcn.org.uk/clinical-topics/infection-prevention-and-control/novel-coronavirus>

Royal College of Physicians. **Specialty-specific guidance on aspects of clinical care and treatment for COVID-19.** <https://www.rcplondon.ac.uk/education-practice/advice/specialty-specific-guidance-aspects-clinical-care-and-treatment-covid-19>

WHO. **Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance.** 13 March 2020. [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected)

### Children & Adolescents

British Paediatric Respiratory Society. **Guidance for the clinical management of children admitted to hospital with suspected COVID-19.** [https://www.rcpch.ac.uk/sites/default/files/2020-03/bprs\\_management\\_of\\_children\\_admitted\\_to\\_hospital\\_with\\_covid19\\_-\\_20200319.pdf](https://www.rcpch.ac.uk/sites/default/files/2020-03/bprs_management_of_children_admitted_to_hospital_with_covid19_-_20200319.pdf)

Goldman PS, van Ijzendoorn MH, Sonuga-Barke EJS. **The implications of COVID-19 for the care of children living in residential institutions.** The Lancet Child and Adolescent Health. [https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(20\)30130-9/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30130-9/fulltext)

Jones VG, Mills M, Suarez D, et al. **COVID-19 and Kawasaki disease: novel virus and novel case.** Hosp Pediatr. 2020; doi: 10.1542/hpeds.2020-0123 (This is a pre-publication version of an article that has undergone peer review and been accepted for publication but is not the final version of record) <https://hosppeds.aappublications.org/content/hosppeds/early/2020/04/06/hpeds.2020-0123.full.pdf>

Liao J et al. **Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults.** 12 March 2020 (*Please note this is a preprint and has not been certified by peer review. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice*) <https://www.medrxiv.org/content/10.1101/2020.03.10.20032136v1.full.pdf+html>

Ma, H., Hu, J., Tian, J. et al. **A single-center, retrospective study of COVID-19 features in children: a descriptive investigation.** BMC Med 18, 123 (2020). <https://doi.org/10.1186/s12916-020-01596-9>

Paediatric Intensive Care Society. **PICS Statement: Increased number of reported cases of novel presentation of multisystem inflammatory disease.** 27 April 2020. <https://picsociety.uk/wp-content/uploads/2020/04/PICS-statement-re-novel-KD-C19-presentation-v2-27042020.pdf>

Pathak EB et al. **Covid-19 in Children in the United States. Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020.** Journal of Public Health Management and Practice: April 16, 2020 - Volume Publish Ahead of Print  
[https://journals.lww.com/jphmp/Abstract/publishahead/COVID\\_19\\_in\\_Children\\_in\\_the\\_United\\_States\\_.99293.aspx](https://journals.lww.com/jphmp/Abstract/publishahead/COVID_19_in_Children_in_the_United_States_.99293.aspx)

### Care of recovering patients

Stam HJ, Stucki G, Bickenbach J. **Covid-19 and Post Intensive Care Syndrome: A Call for Action.** J Rehabil Med. 2020 Apr 15;52(4):jrm00044.  
<https://www.ncbi.nlm.nih.gov/pubmed/32286675>

### ETHICAL ISSUES

BMA. **BMA Guidance COVID-19: ethical issues.** 3 April 2020.  
<https://www.bma.org.uk/advice-and-support/covid-19/ethics/covid-19-ethical-issues>

BMA. **COVID-19 Ethical Issues . A guidance note**  
<https://www.bma.org.uk/media/2226/bma-covid-19-ethics-guidance.pdf>

Royal College of Physicians. **Ethical Dimensions of Covid-19 for frontline staff.**  
<https://www.rcplondon.ac.uk/news/ethical-guidance-published-frontline-staff-dealing-pandemic>

Royal College of Psychiatrists. **COVID-19: Ethical Considerations.**  
<https://www.rcpsych.ac.uk/about-us/responding-to-covid-19/responding-to-covid-19-guidance-for-clinicians/covid-19-ethical-considerations>

Sokol D. **Decision Making for Intensive Care Triage in COVID-19 Emergency. A practical Guide for Clinicians and Hospital Managers.** April 2020.  
<http://medicalethicist.net/wp-content/uploads/2016/06/v5-Sokol-ICU-Triage-April-2020.pdf>

### VENTILATORS

Truog, RD, Mitchell, C & Daley, GQ. **The Toughest Triage — Allocating Ventilators in a Pandemic.** March 23, 2020 New England Journal of Medicine.  
<https://www.nejm.org/doi/full/10.1056/NEJMp2005689>



Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva [SIAARTI]).

**Clinical ethics recommendations for the allocation of intensive care treatments, in exceptional, resource-limited circumstances.**

<http://www.siaarti.it/SiteAssets/News/COVID19%20-%20documenti%20SIAARTI/SIAARTI%20-%20Covid-19%20-%20Clinical%20Ethics%20Reccomendations.pdf>

## **CARE OF HEALTH-CARE STAFF.**

Royal College of Psychiatrists. **Workforce - COVID-19 guidance for clinicians. (Top 10 messages for supporting healthcare staff during the Covid-19 pandemic).** 9 April 2020.

<https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcpsych.ac.uk%2Fabout-us%2Fresponding-to-covid-19%2Fresponding-to-covid-19-guidance-for-clinicians%2Fworkforce-covid-19-guidance-for-clinicians&data=02%7C01%7Crichard.williams%40southwales.ac.uk%7Cecbb07c6b4214b30214808d7d2765daf%7Ce5aafe7c971b4ab7b039141ad36acec0%7C0%7C1%7C637209278141940935&sdata=pwJb9nhRFWkJBRwltsLVE6%2F3Odv98yMCB%2Fg9ih6XFWl%3D&reserved=0>

ICRC. **COVID-19 and Violence Against Health-Care – Safer COVID-19 Response: Checklist for Health-Care Services.** 4 May 2020.

<https://www.icrc.org/en/publication/covid-19-and-violence-against-health-care-safer-covid-19-response-checklist-health-care>

## **INFECTION CONTROL**

Public Health England. **COVID-19: infection prevention and control (IPC).**

Updated 12 April 2020. <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control>

ECDC. (European Centers for Disease Prevention and Control). **Infection Prevention and Control and preparedness for COVID-19 in health care settings.** Second update 31 March 2020.

[https://www.ecdc.europa.eu/sites/default/files/documents/Infection-prevention-control-for-the-care-of-patients-with-2019-nCoV-healthcare-settings\\_update-31-March-2020.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/Infection-prevention-control-for-the-care-of-patients-with-2019-nCoV-healthcare-settings_update-31-March-2020.pdf)

Centers for Disease Control and Prevention. **Coronavirus disease 2019 (COVID-19).** Updated 13 April 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html>



Al-Tawfiq JA, Memish ZA. **Guide to infection control in the healthcare setting. Covid-19, the 2019-novel coronavirus (2019-NCOV, SARS-CoV-2)**

Ed: Mehtar S. International Society for Infectious Diseases 2020.

<https://isid.org/guide/pathogens/covid19/>

Chin AWH *et al.* **Stability of SARS-CoV-2 in different environmental conditions.**

The Lancet Microbe. 2 April 2020

<https://www.sciencedirect.com/science/article/pii/S2666524720300033?via%3Dihub>

Guo Z-D *et al.* **Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020.** EID Journal

26, No 7: [https://wwwnc.cdc.gov/eid/article/26/7/20-0885\\_article](https://wwwnc.cdc.gov/eid/article/26/7/20-0885_article)

Kampf G *et al.* **Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.** Journal of Hospital Infection 104,3; March 2020.

246-251. [https://www.journalofhospitalinfection.com/article/S0195-6701\(20\)30046-3/fulltext](https://www.journalofhospitalinfection.com/article/S0195-6701(20)30046-3/fulltext)

Leung, N.H.L., Chu, D.K.W., Shiu, E.Y.C. *et al.* **Respiratory virus shedding in exhaled breath and efficacy of face masks.** *Nat Med* (2020).

<https://doi.org/10.1038/s41591-020-0843-2>

Srivatsan S *et al.* **Preliminary support for a “dry swab, extraction free” protocol for SARS-CoV-2 testing via RT-qPCR.** (This article is a preprint and has not been certified by peer review).

<https://www.biorxiv.org/content/10.1101/2020.04.22.056283v1>

van Doremalen N *et al.* **Aerosol and surface stability of SARS-CoV-2 as compared to SARS-CoV-1.** *NEJM* 17 March 2020.

<https://www.nejm.org/doi/full/10.1056/NEJMc2004973>

### **PPE and Masks**

BMJ. **Face masks for the public during the covid-19 crisis.** *BMJ*

2020;369:m1435. <https://www.bmj.com/content/369/bmj.m1435>

ECDC (European Centre for Disease Prevention and Control). **Cloth masks and mask sterilisation as options in case of shortage of surgical masks and respirators.** 26 March 2020. <https://www.ecdc.europa.eu/en/publications-data/cloth-masks-sterilisation-options-shortage-surgical-masks-respirators>

ECDC. **Using face masks in the community. Reducing COVID-19 transmission from potentially asymptomatic or pre-symptomatic people through the use of face masks.** 8 April 2020.

<https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-use-face-masks-community.pdf>

ECDC. **Guidance for wearing and removing personal protective equipment in healthcare settings for the care of patients with suspected or confirmed COVID-19.** February 2020.

<https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-guidance-wearing-and-removing-personal-protective-equipment-healthcare-settings-updated.pdf>

Feng S et al. **Rational use of face masks in the COVID-19 pandemic.** Published: March 20, 2020 DOI: [https://doi.org/10.1016/S2213-2600\(20\)30134-X](https://doi.org/10.1016/S2213-2600(20)30134-X)

Howard, J. et al. **Face Masks Against COVID-19: An Evidence Review.** *Preprints* 2020, 2020040203 (doi: 10.20944/preprints202004.0203.v1). <https://www.preprints.org/manuscript/202004.0203/v1>

PHE. **COVID-19 personal protective equipment (PPE).** (Updated 7 April 2020) <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-personal-protective-equipment-ppe>

WHO **Advice on the use of masks in the context of Covid-19.** 6<sup>th</sup> April 2020. [https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-\(2019-ncov\)-outbreak](https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak)

WHO. **Infection prevention and control during health care when Covid-19 is suspected.** 19<sup>th</sup> March 2020. [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)

## **LOW INCOME SETTINGS**

### **Refugees and refugee camps**

Ayebare RR. **Adoption of COVID-19 triage strategies for low income settings.** *Lancet Respir Med* 2020;8:e11-e12. [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30114-4/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30114-4/fulltext)

Cranfield University. **Protecting refugees during COVID-19.** 8 April 2020. <https://www.cranfield.ac.uk/press/news-2020/protecting-refugees-during-covid-19>  
Dahab N et al. **COVID-19 control in low-income settings and displaced populations: what can realistically be done?** 30 March 2020 (update 2 April 2020) <https://www.lshtm.ac.uk/newsevents/news/2020/covid-19-control-low-income-settings-and-displaced-populations-what-can>

IASC. **Interim guidance: Scaling-up COVID-19 outbreak readiness and response operations in humanitarian situations including camps and camp-like settings (Version 1.1, March 2020).** <https://reliefweb.int/report/world/interim-guidance-scaling-covid-19-outbreak-readiness-and-response-operations>

IASC. **Interim Guidance on Public Health and Social Measures for COVID-19 Preparedness and Response Operations in Low Capacity and Humanitarian Settings.** 6 May 2020. <https://interagencystandingcommittee.org/health/interim-guidance-public-health-and-social-measures-covid-19-preparedness-and-response>

Refugees International. **COVID-19 and the displaced: addressing the threat of the novel coronavirus in humanitarian emergencies.** 30 March 2020. <https://www.refugeesinternational.org/reports/2020/3/29/covid-19-and-the-displaced-addressing-the-threat-of-the-novel-coronavirus-in-humanitarian-emergencies>

UNSW Sydney, Kaldor Centre for International Refugee Law. **Considering the impact of COVID-19 on refugees.** <https://www.kaldorcentre.unsw.edu.au/news/considering-impact-covid-19-refugees>

## Sphere

Sphere. **Covid-19 guidance based on humanitarian standards.** <https://spherestandards.org/coronavirus>

## THE VIRUS

### General

Bryner J. **The coronavirus did not escape from a lab. Here's how we know.** Live Science 23 March 2020. <https://www.livescience.com/coronavirus-not-human-made-in-lab.html?fbclid=IwAR1tWkfVZv8c19U5EyWjFbQ5ibTlhwHLRoF6M5mSLxFz7ysysWMDUzXV4>

Calisher C. et al. **Statement in support of the scientists, public health professionals and medical professionals of China combatting COVID-19.** 19 February 2020. Lancet. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30418-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30418-9/fulltext)

Wölfel, R., Corman, V.M., Guggemos, W. et al. **Virological assessment of hospitalized patients with COVID-2019.** *Nature* (2020). <https://doi.org/10.1038/s41586-020-2196-x>

## Epidemiology

Chan J F-W et al. **A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.** Lancet VOLUME 395, ISSUE 10223, P514-523, FEBRUARY 15, 2020 DOI: [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9)

Chen N *et al.* **Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.** The Lancet 30 Jan 2020. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30211-7/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext)

Deslandes A *et al.* **SARS-CoV-2 was already spreading in France in late December 2019.** International Journal of Antimicrobial Agents 3 May 2020 <https://www.sciencedirect.com/science/article/pii/S0924857920301643>

Giordano, G., Blanchini, F., Bruno, R. *et al.* **Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy.** *Nat Med* (2020). <https://doi.org/10.1038/s41591-020-0883-7>

Gudbjartsson DF *et al.* **Spread of SARS-CoV-2 in the Icelandic Population.** New England Journal of Medicine. 14 April 2020 <https://www.nejm.org/doi/full/10.1056/NEJMoa2006100>

He X *et al.* **Temporal dynamics in viral shedding and transmissibility of COVID-19.** 15 April 2020. Nature Medicine brief communication. <https://www.nature.com/articles/s41591-020-0869-5>

Jarvis CI *et al.* **Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK.** (Non-peer reviewed preprint.) 3 April 2020. medRxiv 2020.03.31.20049023; doi: <https://doi.org/10.1101/2020.03.31.20049023>

Pung R *et al.* **Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures.** 16 March 2020. [https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736\(20\)30528-6/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS0140-6736(20)30528-6/fulltext)

## Immunology

Giamarellos-Bourboulis EJ *et al.* **Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.** (In Press – corrected proof) *Cell Host & Microbe* 2020. <https://doi.org/10.1016/j.chom.2020.04.009>

Risitano, A.M., Mastellos, D.C., Huber-Lang, M. *et al.* **Complement as a target in COVID-19?** *Nat Rev Immunol* (2020). <https://doi.org/10.1038/s41577-020-0320-7>  
Wang X *et al.* **SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion.** 7 April 2020 *Nature Cellular and Molecular Immunology*. <https://www.nature.com/articles/s41423-020-0424-9>

## Drug & other interactions

de Castro MJ, Pardo-Seco J, Martín-Torres F. **Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis.** *Clin Infect Dis*. 2015 Jun 1;60(11):1611-9. doi: 10.1093/cid/civ144. Epub 2015 Feb 27 <https://www.ncbi.nlm.nih.gov/pubmed/25725054>

Li J et al. **Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.** *JAMA Cardiol.* Published online April 23, 2020. doi:10.1001/jamacardio.2020.1624  
<https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049>

Mancia G et al. **Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19.** *New England Journal of Medicine.* 1 May 2020.  
<https://www.nejm.org/doi/full/10.1056/NEJMoa2006923>

Miller A et al. **Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study.** doi: <https://doi.org/10.1101/2020.03.24.20042937>

Reynolds HR et al. **Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19.** *New England Journal of Medicine.* 1 May 2020. medRxiv May 2020  
<https://www.nejm.org/doi/full/10.1056/NEJMoa2008975>

## VACCINES, TESTS & TREATMENTS

### Vaccines

Than Le T et al. **The COVID-19 vaccine development landscape.** *Nature* 9 April 2020. <https://www.nature.com/articles/d41573-020-00073-5>

### Therapeutics

CDC. **Information for clinicians on Investigational Therapeutics for Patients with COVID-19.** 13 April 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>

Chen L et al. **Convalescent plasma as a potential therapy for COVID-19.** 27 February 2020. *Lancet.* [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30141-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30141-9/fulltext)

Duan K et al. **Effectiveness of convalescent plasma therapy in severe COVID-19 patients.** *PNAS* 18 March 2020.  
<https://www.pnas.org/content/early/2020/04/02/2004168117>

Mehta P, McAuley DF, Brown M, et al. **COVID-19: consider cytokine storm syndromes and immunosuppression.** *Lancet* 2020 Mar 28;395(10229): 1033-1034. [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)

Norrie JD. **Remdesivir for COVID-19: challenges of underpowered studies.** *The Lancet* 29 April 2020. DOI:[https://doi.org/10.1016/S0140-6736\(20\)31023-0](https://doi.org/10.1016/S0140-6736(20)31023-0)

Wang Y et al. **Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.** The Lancet 29 April 2020. DOI: [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9)

### **Antimalarials & other drugs**

BMJ Editorial. **Chloroquine and hydroxychloroquine in covid-19.** 8 April 2020. *BMJ* 2020; 369 doi: <https://doi.org/10.1136/bmj.m1432>

Caly, L et al. **The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.** *Antiviral Research Volume 178*, June 2020, 104787 <https://doi.org/10.1016/j.antiviral.2020.104787>

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. **A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.** *J Crit Care.* 2020;57: 279-283. doi: [10.1016/j.jcrc.2020.03.005](https://doi.org/10.1016/j.jcrc.2020.03.005)

D'Alessandro S, Scaccabarozzi D, Signorini L, et al. **The Use of Antimalarial Drugs against Viral Infection.** *Microorganisms.* 2020;8(1):85. Published 2020 Jan 8. <https://pubmed.ncbi.nlm.nih.gov/31936284/>

Frieden TR, Lee CT. **Identifying and Interrupting Superspreading Events—Implications for Control of Severe Acute Respiratory Syndrome Coronavirus 2.** *Emerg Infect Dis.* 2020;26(6):1059-1066. <https://dx.doi.org/10.3201/eid2606.200495>

Gautret P et al. **Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial.** *Int J Antimicrob Agents* 2020; Mar 20. DOI: [10.1016/j.ijantimicag.2020.105949](https://doi.org/10.1016/j.ijantimicag.2020.105949)

Geleris J et al. **Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.** *New England Journal of Medicine.* 7 May 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2012410>

Jaffe S. **Regulators split on antimalarials for COVID-19.** 11 April 2020. *Lancet.* [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30817-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30817-5/fulltext)

Joseph M et al. **Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19** (Preprint not certified by peer review) doi: <https://doi.org/10.1101/2020.04.16.20065920>

Kelleni MT. **Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management.** *Pharmacological Research Volume 157*, 2020, 104874. <https://doi.org/10.1016/j.phrs.2020.104874>

Lane J.C.E. et al. **Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study.** (Preprint not certified by peer review) medRxiv doi: [10.1101/2020.04.08.20054551](https://doi.org/10.1101/2020.04.08.20054551)



Mayla GSB et al. **Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).** (Preprint not certified by peer review) medRxiv  
doi: [10.1101/2020.04.07.20056424](https://doi.org/10.1101/2020.04.07.20056424)

Million M et al. **Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.** (In Press) Travel Medicine and Infectious Disease, May 2020  
<https://doi.org/10.1016/j.tmaid.2020.101738>

The Pharmaceutical Journal. **Could chloroquine be effective against COVID-19?** 3 April 2020. <https://www.pharmaceutical-journal.com/news-and-analysis/opinion/correspondence/could-chloroquine-be-effective-against-covid-19/20207868.article?firstPass=false>

Principi N, Esposito S. **Chloroquine or hydrochloroquine for prophylaxis of COVID-19.** Lancet Infectious Diseases. April 17, 2020 DOI: [https://doi.org/10.1016/S1473-3099\(20\)30296-6](https://doi.org/10.1016/S1473-3099(20)30296-6)

Silva Borba MG et al. **Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A randomized clinical trial.** JAMA Netw Open 2020;3(4.23):2e208857  
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499>

Touret F, de Lamballerie X. **Of chloroquine and COVID-19.** Antiviral Res. 2020 Mar 5;177. <https://www.ncbi.nlm.nih.gov/pubmed/32147496>

Tucker R. **Chloroquine in severe COVID-19: reviewing the evidence.** Hospital HealthCare Europe. 6 May 2020. <https://hospitalhealthcare.com/covid-19/chloroquine-in-severe-covid-19-reviewing-the-evidence/>

## Tests & Testing

CIDRAP. **Antibody tests may hold clues to COVID-19 exposure, immunity – but it's complicated.** CIDRAP News 15 April 2020. <https://www.cidrap.umn.edu/news-perspective/2020/04/antibody-tests-may-hold-clues-covid-19-exposure-immunity>

FIND. **SARS-CoV-2 diagnostic pipeline.** (An overview of all SARS-CoV-2 tests commercially available or in development for the diagnosis of COVID-19).  
<https://www.finddx.org/covid-19/covid-19-backup/pipeline-2/>

Johns Hopkins, Bloomberg School of Public Health. **Serology-based tests for COVID-19.** 15 April 2020. <https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html>



Sethuraman N et al. **Interpreting Diagnostic Tests for SARS-CoV-2.** JAMA. Published online May 6, 2020. [doi:10.1001/jama.2020.8259](https://doi.org/10.1001/jama.2020.8259)

UK Government. **COVID-19: guidance for sampling and for diagnostic laboratories. (Information for clinical diagnostic laboratories regarding safety, sampling and packaging specimens associated with COVID-19).** 15 January 2020. [https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories?utm\\_campaign=11461808\\_COVID-19%20webinars%20w%2Fc%207%20April&utm\\_medium=email&utm\\_source=Biological%20Industry%20Association&dm\\_i=1TUV,6TNZK,TC908Y,RC8E6,1](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories?utm_campaign=11461808_COVID-19%20webinars%20w%2Fc%207%20April&utm_medium=email&utm_source=Biological%20Industry%20Association&dm_i=1TUV,6TNZK,TC908Y,RC8E6,1)

UK Government. **Guidance on coronavirus (COVID-19) tests and testing kits. (Initial specifications for tests and testing kits and advice for members of the public).** 13 April 2020. <https://www.gov.uk/guidance/guidance-on-coronavirus-covid-19-tests-and-testing-kits>

WHO. **WHO lists two COVID-19 tests for emergency use.** 7 April 2020. <https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use>

## MISCELLANEOUS

### Environment, Animals

Conticini E et al. **Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy.** Science Direct. 4 April 2020. <https://doi.org/10.1016/j.envpol.2020.114465>

Ogen Y. **Assessing nitrogen dioxide (NO<sub>2</sub>) levels as a contributing factor to coronavirus (COVID-19) fatality.** *Sci Total Environ.* 2020 Apr 11;726:138605. doi: 10.1016/j.scitotenv.2020.138605. [Epub ahead of print]. <https://www.ncbi.nlm.nih.gov/pubmed/32302812>

OIE (World Organisation for Animal Health). **Considerations for sampling, testing, and reporting of SARS-CoV-2 in animals.** Version 1 7 May 2020. [https://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/COVID-19/Sampling\\_Testing\\_and\\_Reporting\\_of\\_SARS-CoV-2\\_in\\_animals\\_final\\_7May\\_2020.pdf](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COVID-19/Sampling_Testing_and_Reporting_of_SARS-CoV-2_in_animals_final_7May_2020.pdf)

WHO. **Cleaning and disinfection of environmental surfaces in the context of COVID-19.** 16 May 2020. <https://www.who.int/publications-detail/cleaning-and-disinfection-of-environmental-surfaces-in-the-context-of-covid-19>

### Mass Gatherings

WHO. **Considerations in adjusting public health and social measures in the context of COVID-19 (Interim Guidance).** Geneva, 2020 <https://www.who.int/publications-detail/considerations-in-adjusting-public-health-and-social-measures-in-the-context-of-covid-19-interim-guidance>

WHO. **Key planning recommendations for Mass Gatherings in the context of the current COVID-19 outbreak (Interim Guidance).** Geneva 2020  
(<https://www.who.int/publications-detail/key-planning-recommendations-for-mass-gatherings-in-the-context-of-the-current-covid-19-outbreak>)

WHO. **Critical preparedness, readiness and response actions for COVID-19 (Interim Guidance).** Geneva, 2020 <https://www.who.int/publications-detail/critical-preparedness-readiness-and-response-actions-for-covid-19>

WHO. **How to use WHO risk assessment and mitigation checklist for Mass Gatherings in the context of COVID-19 (Interim Guidance).** Geneva 2020  
(<https://www.who.int/publications-detail/how-to-use-who-risk-assessment-and-mitigation-checklist-for-mass-gatherings-in-the-context-of-covid-19>),

WHO. **Mass Gatherings risk assessment COVID-19: Key considerations (Excel tool).** Geneva, 2020 <https://www.who.int/who-documents-detail/mass-gathering-risk-assessment-covid-19-key-considerations>

WHO. **Decision tree flow chart for mass gatherings in the context of COVID-19.** Geneva 2020 <https://www.who.int/who-documents-detail/decision-tree-for-risk-assessment-for-mass-gathering>

WHO. **Public Health for Mass Gatherings: Key Considerations.** Geneva, 2015  
[https://www.who.int/ihr/publications/WHO\\_HSE\\_GCR\\_2015.5/en/](https://www.who.int/ihr/publications/WHO_HSE_GCR_2015.5/en/)

WHO. **Considerations for Mass Gatherings in the context of COVID-19. Annex: Considerations in adjusting public health and social measures in the context of COVID-19.** Geneva 14 May 2020.  
[https://apps.who.int/iris/bitstream/handle/10665/332079/WHO-2019-nCoV-Adjusting\\_PH\\_measures-Mass\\_gatherings-2020.1-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/332079/WHO-2019-nCoV-Adjusting_PH_measures-Mass_gatherings-2020.1-eng.pdf?sequence=1&isAllowed=y)

### **Treatment, Health Care etc.**

Ahmad A et al. **What does it mean to be vulnerable in the era of COVID-19.** The Lancet 27 April 2020. DOI:[https://doi.org/10.1016/S0140-6736\(20\)30979-X](https://doi.org/10.1016/S0140-6736(20)30979-X)  
BSGM. (The British Society for Genetic Medicine). **BSGM Guidance on Shielding for vulnerable patients.** 14 April 2020. <https://www.bsgm.org.uk/news/bsgm-guidance-on-shielding-for-vulnerable-patients/>

Burki T. **Prisons are “in no way equipped” to deal with COVID-19.** The Lancet VOLUME 395, ISSUE 10234, P1411-1412, MAY 02, 2020.  
DOI:[https://doi.org/10.1016/S0140-6736\(20\)30984-3](https://doi.org/10.1016/S0140-6736(20)30984-3)

Cennimo DJ. **Coronavirus Disease 2019 (COVID-19) Treatment & Management.** Updated 27 Apr 2020. <https://emedicine.medscape.com/article/2500114-treatment>

The Lancet Editorial. **Redefining vulnerability in the era of COVID-19. The Lancet.** VOLUME 395, ISSUE 10230, P1089, APRIL 04, 2020.  
DOI: [https://doi.org/10.1016/S0140-6736\(20\)30757-1](https://doi.org/10.1016/S0140-6736(20)30757-1)

## IHL & other Legal

ICRC. **COVID-19: How IHL provides crucial safeguards during pandemics.** 31 March 2020. [https://www.icrc.org/en/document/covid-19-how-ihl-provides-crucial-safeguards-during-pandemics?utm\\_campaign=DP\\_FORUM%20-%20%20%20COVID-19%20response%20in%20conflict%20zones%20hinges%20on%20respect%20for%20international%20humanitarian%20law&utm\\_source=hs\\_email&utm\\_medium=email&utm\\_content=86397599&hsenc=p2ANq](https://www.icrc.org/en/document/covid-19-how-ihl-provides-crucial-safeguards-during-pandemics?utm_campaign=DP_FORUM%20-%20%20%20COVID-19%20response%20in%20conflict%20zones%20hinges%20on%20respect%20for%20international%20humanitarian%20law&utm_source=hs_email&utm_medium=email&utm_content=86397599&hsenc=p2ANq)

ICRC. **COVID-19 response in conflict zones hinges on respect for international humanitarian law.** 16 April 2020. [https://blogs.icrc.org/law-and-policy/2020/04/16/covid-19-response-respect-international-humanitarian-law/?utm\\_campaign=DP\\_FORUM%20-%20%20%20COVID-19%20response%20in%20conflict%20zones%20hinges%20on%20respect%20for%20international%20humanitarian%20law&utm\\_source=hs\\_email&utm\\_medium=email&utm\\_content=86397599&](https://blogs.icrc.org/law-and-policy/2020/04/16/covid-19-response-respect-international-humanitarian-law/?utm_campaign=DP_FORUM%20-%20%20%20COVID-19%20response%20in%20conflict%20zones%20hinges%20on%20respect%20for%20international%20humanitarian%20law&utm_source=hs_email&utm_medium=email&utm_content=86397599&)

## Taxonomy & genetics

Gorbalenya A. et al. **Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group.** <https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1.full.pdf>

Van Dorp L et al. **Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.** Infect Genet Evol. 2020 May 5 : 104351.  
doi: [10.1016/j.meegid.2020.104351](https://doi.org/10.1016/j.meegid.2020.104351) [Epub ahead of print]

Yao H et al. **Patient-derived mutations impact pathogenicity of SARS-CoV-2.** (Please note this is a preprint and has not been certified by peer review. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice)  
<https://www.medrxiv.org/content/10.1101/2020.04.14.20060160v2>

Yong Jia et al. **Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of 2 RBD mutant with lower ACE2 binding affinity.** doi: <https://doi.org/10.1101/2020.04.09.034942> [This article is a preprint and has not been certified by peer review]

## Other pathogens

WHO. **Tailoring malaria interventions in the COVID-19 response**

<https://www.who.int/malaria/publications/atoz/tailoring-malaria-interventions-in-the-covid-19-response/en/>

WHO. Information Note. **Tuberculosis and COVID-19**. 4 April 2020.

[https://www.who.int/tb/COVID\\_19considerations\\_tuberculosis\\_services.pdf](https://www.who.int/tb/COVID_19considerations_tuberculosis_services.pdf)

WHO. Scientific Brief. **Bacille Calmet-Guérin (BCG) vaccination and COVID-19**.

12 April 2020. [https://www.who.int/news-room/commentaries/detail/bacille-calmette-guérin-\(bcg\)-vaccination-and-covid-19](https://www.who.int/news-room/commentaries/detail/bacille-calmette-guérin-(bcg)-vaccination-and-covid-19)

## Press & publications

NHS Providers. **Confronting Coronavirus in the NHS**.

<https://nhsproviders.org/confronting-coronavirus-in-the-nhs>

The New Humanitarian (formerly IRIN News): <https://www.thenewhumanitarian.org>

The New York Times. **Hoping Llamas Will Become Coronavirus Heroes**. 6 May

2020. <https://www.nytimes.com/2020/05/06/science/llama-coronavirus-antibodies.html>

ODI Newsletter – weekly. To sign up: <https://www.odi.org/newsletter-sign-up>

WHO. **Q & A on coronaviruses (COVID-19)**. 8 April 2020.

<https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>

Levitan R. **The Infection that's Silently Killing Coronavirus Patients** (Silent Hypoxia). New York Time Op Ed. 20 April 2020.

<https://www.nytimes.com/2020/04/20/opinion/coronavirus-testing-pneumonia.html>

Nature News. **Coronavirus blood-clot mystery intensifies**. 8 May 2020.

<https://www.nature.com/articles/d41586-020-01403-8>

Saplakoglu Y. **Recovered patients who tested positive for COVID-19 likely not reinfected**. LiveScience May 2020. <https://bit.ly/3fjZ7hE>

Woodruff Swan B et al. **Poop could help stop the pandemic. Really**. Politico May

2020. <https://www.politico.com/news/2020/05/01/cdc-human-waste-coronavirus-222253>

## ON-LINE COURSES, WEBINARS, BLOGS & BOOKS

### Courses

LSHTM. **COVID-19: Tackling the Novel Coronavirus.**

<https://www.futurelearn.com/courses/covid19-novel-coronavirus>

redr uk. **Covid-19 training. Free online training courses for a UK based audience:**

Module 1: Culturally Appropriate Hygiene Promotion for Covid-19

Module 2: Covid-19 Myth Busting

Module 3: Managing Stress During the Covid-19 Pandemic

<https://www.redr.org.uk/Training-Learning/Covid-19-Training>

Royal College of Physicians and Surgeons of Glasgow. **Covid-19 Resource pages. Training and Assessment updates.** <https://rcpsg.ac.uk/covid-19>

SGUL. **Managing COVID-19 in General Practice.**

<https://www.futurelearn.com/courses/management-of-covid-19-in-general-practice>

WHO. **Coronavirus disease (COVID-19) training: Online training.**

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/training/online-training>

Courses include:

- Severe Acute Respiratory Infection (SARI) Treatment Facility Design
- COVID-19: Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response
- Infection Prevention and Control (IPC) for novel coronavirus (COVID-19)
- Introduction to emerging respiratory viruses, including novel coronavirus
- Clinical Care Severe Acute Respiratory Infection
- WHO-ICRC Basic Emergency Care: approach to the acutely ill and injured
- WHO Medical Emergency Checklist
- Resuscitation Area Designation Tool
- Health and safety briefing for respiratory diseases – ePROTECT

### Blogs

World Extreme Medicine. **Blog.** <https://worldextrememedicine.com/blog/tag/covid-19/>

## Webinars

RSM. **COVID-19 Series.** (This webinar series is dedicated to give healthcare workers on the frontlines, regular and easy-to-access updates from healthcare leaders on COVID-19). [https://www.rsm.ac.uk/resources/rsm-live/?\\_cldee=bWFyaW9uLmJpcmNoMkBidGludGVybmV0LmNvbQ%3d%3d&recipe\\_ntid=contact-48958b9efc22e911a88100224800492f-07fc18bd6f7c468893d2bce9906d2412&utm\\_source=ClickDimensions&utm\\_medium=email&utm\\_campaign=PEN65%20%26%20PEN66%2018.4.2020&esid=c144d41e-c780-ea11-a811-000d3a86ad99](https://www.rsm.ac.uk/resources/rsm-live/?_cldee=bWFyaW9uLmJpcmNoMkBidGludGVybmV0LmNvbQ%3d%3d&recipe_ntid=contact-48958b9efc22e911a88100224800492f-07fc18bd6f7c468893d2bce9906d2412&utm_source=ClickDimensions&utm_medium=email&utm_campaign=PEN65%20%26%20PEN66%2018.4.2020&esid=c144d41e-c780-ea11-a811-000d3a86ad99)

## UNIVERSITIES

Birmingham University. **COVID-19 research.**  
<https://www.birmingham.ac.uk/research/coronavirus/index.aspx>

Cambridge University. **Research Covid-19.** <https://www.cam.ac.uk/topics/covid-19>

Edinburgh University. Usher Institute. Acute Care Edinburgh. **The COVID-19 Research Group.** <https://www.ed.ac.uk/usher/acute-care-edinburgh/world-class-research/the-covid-19-research>

Glasgow University. **Centre for Virus Research.**  
<https://www.gla.ac.uk/researchinstitutes/iii/cvr/researchprogrammes/covid/>

Liverpool University & Liverpool School of Tropical Medicine. **CEIDR and HPRU EZI COVID-19 research programme.** <https://www.liverpool.ac.uk/centre-of-excellence-infectious-diseases-research/covid-19/>  
& <https://www.lstmed.ac.uk/covid-19>

Manchester University. **Biology Medicine and Health. Covid-19 research rapid response group.** <https://www.manchester.ac.uk/coronavirus-response/bmh-coronavirus-projects/>

Oxford University. **Coronavirus research.**  
<https://www.research.ox.ac.uk/Area/coronavirus-research>

## London University

Imperial College. **MRC Centre for Global Infectious Disease Analysis.**  
<https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/covid-19-reports/>

Kings College. **Research Portal.**  
<https://kclpure.kcl.ac.uk/portal/en/search.html?searchall=covid-19>

LSHTM. **COVID-19.** <https://www.lshtm.ac.uk/research/research-action/covid-19>

UCL. **COVID-19 Research at UCL.** <https://www.ucl.ac.uk/covid-19-research/>

## BOOKS

Arnold C. **Pandemic 1918: The Story of the Deadliest Influenza in History.**  
Michael O'Mara Books Ltd. 2018

Kelman L. **Disaster by Choice.** OUP 2020  
<https://global.oup.com/academic/product/disaster-by-choice-9780198841340?cc=gb&lang=en&>

Kucharski A. **The Rules of Contagion: Why Things Spread - and Why They Stop.**  
Profile Books. Wellcome Collection 2020. <https://profilebooks.com/the-rules-of-contagion.html>